<DOC>
	<DOCNO>NCT00404742</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy LX211 therapy subject clinically quiescent non-infectious uveitis</brief_summary>
	<brief_title>A Study LX211 Clinically Quiescent Non-infectious Intermediate , Anterior Intermediate , Posterior Pan-Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Uveitis , Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<criteria>A documented history noninfectious intermediate , anterior intermediate , posterior panuveitis . Minimum prescribed therapy upon enrollment one following : systemic prednisone equivalent average ≥ 10 mg/day least 2 periocular/intravitreal corticosteroid administration control inflammatory disease within previous 8 month ( within 6 week randomization ) . least one , 2 immunosuppressive drug among follow compound : cyclosporine , tacrolimus , azathioprine , mycophenolate mofetil , methotrexate Subjects clinically quiescent uveitis eye enrollment stable treatment regimen minimum 6 week Bestcorrected distance visual acuity bad involve eye 20/400 better ( ETDRS logMAR &lt; 1.34 ) Subjects plan undergo elective ocular surgery study Evidence active , uncontrolled noninfectious uveitis Periocular administration corticosteroid within previous 6 week . Uveitis infectious etiology Uncontrolled glaucoma Clinically suspect confirmed central nervous system ocular lymphoma History diagnosis Behçet 's disease Primary diagnosis anterior uveitis</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>uveitis</keyword>
	<keyword>calcineurin</keyword>
</DOC>